SCHEMBL10073043

SCHEMBL10073043

COc1ccc(CCNC(=O)c2cc3ccccc3o2)cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 1.00
L3MBTL1 Q9Y468 2/20 0.79
OPRM1 P35372 1/20 0.71
TMEM97 Q5BJF2 1/20 0.71
SIGMAR1 Q99720 1/20 0.71
ABCG2 Q9UNQ0 2/20 0.65
ABCB1 P08183 1/20 0.64
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
RAB9A P51151 1/20 0.64
MAPT P10636 4/20 0.63
TSHR P16473 2/20 0.63
KDM4E B2RXH2 2/20 0.63
ALDH1A1 P00352 2/20 0.63
HPGD P15428 2/20 0.63
HSD17B10 Q99714 2/20 0.63
TP53 P04637 2/20 0.63
HKDC1 Q2TB90 1/20 0.63
SMN1; SMN2 Q16637 3/20 0.62
POLB P06746 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14985290 0.86 NAMPT (0.76) NAMPTL3MBTL1OPRM1TMEM97SIGMAR1
SCHEMBL2242298 0.81 SMN1; SMN2 (0.74) NAMPTL3MBTL1OPRM1TMEM97SIGMAR1
SCHEMBL6270935 0.79 ALDH1A1 (0.77) NAMPTMEN1KMT2ARAB9AMAPT
SCHEMBL29356619 0.79 ALDH1A1 (0.77) NAMPTMEN1KMT2ARAB9AMAPT
SCHEMBL6038373 0.79 NAMPT (0.64) NAMPTL3MBTL1OPRM1TMEM97SIGMAR1
SCHEMBL557643 0.79 L3MBTL1 (0.67) NAMPTL3MBTL1OPRM1TMEM97SIGMAR1
SCHEMBL10073054 0.78 NAMPT (0.64) NAMPTL3MBTL1OPRM1TMEM97SIGMAR1
SCHEMBL6267575 0.78 CYP1A2 (0.65) NAMPTL3MBTL1ABCG2MEN1KMT2A
SCHEMBL28475160 0.77 NAMPT (0.63) NAMPTL3MBTL1ABCG2MEN1KMT2A
SCHEMBL8099685 0.77 CA1 (0.73) MEN1KMT2AMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130012536-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-10 US disclosed
US-20130012536-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-10 US disclosed
US-20120035179-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2012-02-09 US disclosed
US-20120035179-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2012-02-09 US disclosed
US-20100125090-A1 Modulators of ATP-Binding Cassette Transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-20 US disclosed
US-20100125090-A1 Modulators of ATP-Binding Cassette Transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-20 US disclosed
US-7598412-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-10-06 US disclosed
US-7598412-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012536-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS ABCB11, ABCB1, ABCC5 NAMPT 708/4885L3MBTL1 4414/4885OPRM1 2138/4885
US-20100125090-A1 Modulators of ATP-Binding Cassette Transporters ABCB11, ABCB1, ABCC5 NAMPT 708/4885L3MBTL1 4414/4885OPRM1 2138/4885
US-20120035179-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS ABCB11, ABCB1, ABCC5 NAMPT 708/4885L3MBTL1 4414/4885OPRM1 2138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.